264 related articles for article (PubMed ID: 14599658)
1. Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway.
Jana NR; Nukina N
J Chem Neuroanat; 2003 Oct; 26(2):95-101. PubMed ID: 14599658
[TBL] [Abstract][Full Text] [Related]
2. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
Stenoien DL; Mielke M; Mancini MA
Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
[TBL] [Abstract][Full Text] [Related]
3. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
[TBL] [Abstract][Full Text] [Related]
4. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration.
Berke SJ; Paulson HL
Curr Opin Genet Dev; 2003 Jun; 13(3):253-61. PubMed ID: 12787787
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy.
Abu-Baker A; Messaed C; Laganiere J; Gaspar C; Brais B; Rouleau GA
Hum Mol Genet; 2003 Oct; 12(20):2609-23. PubMed ID: 12944420
[TBL] [Abstract][Full Text] [Related]
6. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity.
Sakahira H; Breuer P; Hayer-Hartl MK; Hartl FU
Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16412-8. PubMed ID: 12189209
[TBL] [Abstract][Full Text] [Related]
7. Assessment of impaired proteasomal function in a cellular model of polyglutamine diseases.
Jana NR; Nukina N
Methods Mol Biol; 2004; 277():287-92. PubMed ID: 15201463
[TBL] [Abstract][Full Text] [Related]
8. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates.
Donaldson KM; Li W; Ching KA; Batalov S; Tsai CC; Joazeiro CA
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8892-7. PubMed ID: 12857950
[TBL] [Abstract][Full Text] [Related]
10. Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo.
Hernández F; Díaz-Hernández M; Avila J; Lucas JJ
Trends Neurosci; 2004 Feb; 27(2):66-9. PubMed ID: 15106649
[TBL] [Abstract][Full Text] [Related]
11. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
Tsai YC; Fishman PS; Thakor NV; Oyler GA
J Biol Chem; 2003 Jun; 278(24):22044-55. PubMed ID: 12676955
[TBL] [Abstract][Full Text] [Related]
12. Inefficient degradation of truncated polyglutamine proteins by the proteasome.
Holmberg CI; Staniszewski KE; Mensah KN; Matouschek A; Morimoto RI
EMBO J; 2004 Oct; 23(21):4307-18. PubMed ID: 15470501
[TBL] [Abstract][Full Text] [Related]
13. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions.
Schmidt T; Lindenberg KS; Krebs A; Schöls L; Laccone F; Herms J; Rechsteiner M; Riess O; Landwehrmeyer GB
Ann Neurol; 2002 Mar; 51(3):302-10. PubMed ID: 11891825
[TBL] [Abstract][Full Text] [Related]
14. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses.
Moore DJ; Dawson VL; Dawson TM
Neuromolecular Med; 2003; 4(1-2):95-108. PubMed ID: 14528055
[TBL] [Abstract][Full Text] [Related]
15. A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells.
Li Z; Arnaud L; Rockwell P; Figueiredo-Pereira ME
J Neurochem; 2004 Jul; 90(1):19-28. PubMed ID: 15198663
[TBL] [Abstract][Full Text] [Related]
16. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation.
Li Z; Jansen M; Pierre SR; Figueiredo-Pereira ME
Int J Biochem Cell Biol; 2003 May; 35(5):547-52. PubMed ID: 12672447
[TBL] [Abstract][Full Text] [Related]
17. Proteasome degrades soluble expanded polyglutamine completely and efficiently.
Michalik A; Van Broeckhoven C
Neurobiol Dis; 2004 Jun; 16(1):202-11. PubMed ID: 15207277
[TBL] [Abstract][Full Text] [Related]
18. Transferring substrates to the 26S proteasome.
Hartmann-Petersen R; Seeger M; Gordon C
Trends Biochem Sci; 2003 Jan; 28(1):26-31. PubMed ID: 12517449
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamine-mediated neurodegeneration: use of chaperones as prevention strategy.
Paul S
Biochemistry (Mosc); 2007 Apr; 72(4):359-66. PubMed ID: 17511600
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the ubiquitin/proteasome system in conformational diseases.
Lindsten K; Dantuma NP
Ageing Res Rev; 2003 Oct; 2(4):433-49. PubMed ID: 14522245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
